Tyrosine Kinase Inhibitor TKI Powder Imatinib Mesylate

Tyrosine Kinase Inhibitor TKI Powder Imatinib Mesylate For Anti Tumor CAS:220127-57-1


Just try a small order to start our cooperation, we will NOT make you down !
Any products interested pls let me know I will give info.in details.
[email protected]
Skype:live:kathelin_4
WhataApp:+8618872220706

Imatinib Introduction
Imatinib, sold under the brand names Gleevec and Glivec, used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).  Due in large part to the development of Gleevec and related drugs having a similar mechanism of action, the five year survival rate for people with chronic myeloid leukemia nearly doubled from 31% in 1993 (before Gleevec's 2001 FDA approval) to 59% for those diagnosed between 2003 and 2009.  Median survival for imatinib-treated people with gastrointestinal stromal tumors (GIST) is nearly 5 years compared to 9 to 20 months in the pre-imatinib-era.

Imatinib Mesylate Basic Info.
Other Name:Glivec;gleevec;imatinib methanesulfonate;imatinib mesilate;Imatinibmesylate;4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate;4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
CAS:220127-57-1
MF:C30H35N7O4S
MW:589.71
Assay:99%min
Appearence:White powder
Drug category:Anti tumor drug
Purpose:A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL).
Imatinib Mesylate Application:
Compared to older drugs imatinib has a relatively benign side effect profile, allowing many patients to live a normal lifestyle.  Imatinib is a tyrosine-kinase inhibitor. It kills cancer cells by blocking the action of tyrosine kinases. In order to survive, cells need signaling through proteins (signal cascade) to keep them alive. Some of the proteins in this cascade use a phosphate group as an "on" switch. This phosphate group is added by a tyrosine kinase enzyme. In healthy cells, these tyrosine kinase enzymes are turned on and off as needed. In Ph-positive CML cells, one tyrosine kinase enzyme, BCR-Abl, is stuck on the "on" position, and keeps adding phosphate groups. Imatinib blocks this BCR-Abl enzyme, and stops it from adding phosphate groups. As a result, these cells stop growing, and even die by a process of cell death (apoptosis).  Because the BCR-Abl tyrosine kinase enzyme exists only in cancer cells and not in healthy cells, imatinib works as a form of targeted therapy-only cancer cells are killed through the drug's action.[6] In this regard, imatinib was one of the first cancer therapies to show the potential for such targeted action, and is often cited as a paradigm for research in cancer therapeutics.